-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on BeOne Medicines, Raises Price Target to $465

Benzinga·11/06/2026 17:57:21
Listen to the news
RBC Capital analyst Leonid Timashev maintains BeOne Medicines (NASDAQ:ONC) with a Outperform and raises the price target from $459 to $465.